Company Analysis

Enlivex Ltd. (ENLV)

Nasdaq: ENLV · Pharmaceutical Preparations · Tel Aviv · filing with the SEC since 2014
Grade4.8
◀ Past 5.1● Present 5.7▶ Future 3.8
6 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

19 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Enlivex Ltd.’s names, not what it holds today.

Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 3 in 2023
Applications published
31
2 of them in 2025
Names they are printed under
4
a subsidiary, a former name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Medical technology6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
ENLIVEX THERAPEUTICS R&D LTD a subsidiary
IL, as the owner printed on each patent
15 granted
19 published
BioBlast Pharma Ltd. a former name
named as the applicant on its applications, in IL
0 granted
8 published
BioBlast Pharma Ltd. a former name
IL, as the owner printed on each patent
4 granted
1 published
ENLIVEX THERAPEUTICS LTD. a former name
named as the applicant on its applications, in IL
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 15, 202512,274,714Early apoptotic cells for use treating sepsisMedical technologyENLIVEX THERAPEUTICS R&D LTD
Apr 9, 202411,951,126Therapeutic apoptotic cells for cancer therapyPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Jan 30, 202411,883,429Therapeutic pooled blood apoptotic cell preparations and uses thereofPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Aug 22, 202311,730,761Combination immune therapy and cytokine control therapy for cancer treatmentMedical technologyENLIVEX THERAPEUTICS R&D LTD
Aug 8, 202311,717,539Combination immune therapy and cytokine control therapy for cancer treatmentMedical technologyENLIVEX THERAPEUTICS R&D LTD
Mar 7, 202311,596,652Early apoptotic cells for use in treating sepsisPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Nov 29, 202211,512,289Combination immune therapy and cytokine control therapy for cancer treatmentPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Nov 15, 202211,497,767Combination immune therapy and cytokine control therapy for cancer treatmentMedical technologyENLIVEX THERAPEUTICS R&D LTD
May 3, 202211,318,163Combination immune therapy and cytokine control therapy for cancer treatmentPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Apr 19, 202211,304,976Combination immune therapy and cytokine control therapy for cancer treatmentMedical technologyENLIVEX THERAPEUTICS R&D LTD
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Aug 14, 20252025/0255901THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITISPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Jun 26, 20252025/0207105FROZEN FORMULATION COMPRISING APOPTOTIC CELLSPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Mar 23, 20232023/0089828USE OF EARLY APOPTOTIC CELLS FOR TREATING COVID-19PharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Mar 16, 20232023/0084027COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENTPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD
Sep 8, 20222022/0280563THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITISMedical technologyENLIVEX THERAPEUTICS R&D LTD
May 5, 20222022/0133799COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENTMedical technologyENLIVEX THERAPEUTICS R&D LTD · patent 12,274,714 granted from it
Jul 29, 20212021/0228633COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENTMedical technologyENLIVEX THERAPEUTICS R&D LTD
Apr 15, 20212021/0106617COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENTMedical technologyENLIVEX THERAPEUTICS R&D LTD · patent 11,000,548 granted from it
Feb 11, 20212021/0038644THERAPEUTIC POOLED BLOOD APOPTOTIC CELL PREPARATIONS AND USES THEREOFPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD · patent 11,883,429 granted from it
Sep 17, 20202020/0289557EARLY APOPTOTIC CELLS FOR USE IN TREATING SEPSISPharmaceuticalsENLIVEX THERAPEUTICS R&D LTD · patent 11,596,652 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ENLV · research, not advice